

Sheffield Formulary

March 2019

INTRODUCTION

The Sheffield Formulary has been produced under the auspices of the Sheffield Area Prescribing Group (APG) and is designed to give clear concise guidance on drug selection.

The formulary contains a list of preferred choices for non-specialist drugs and products, which will be available in both primary and secondary care. Please note that appropriate funding will be made available for all drugs that receive positive NICE technology appraisal, however not all of these drugs will be specifically listed in this non-specialist, primary care formulary.

The choice of preferred drugs has been made on the basis of evidence of clinical efficacy, safety, patient acceptability and cost effectiveness. The contents reflect wide consultation within the city.

Using the Formulary

Medicines are presented according to the BNF legacy classification. In the majority of cases generic drug names are used. Brand names are given when brand prescribing is advocated for clinical reasons, or if prescribing by brand name is the most cost-effective way to prescribe a particular product.

Drugs, devices or products shown in bold type are those that are recommended for 'first line' use.

Formulations, strengths and pack sizes have been included where considered significant.

In Sheffield, in line with NHSE guidance we recommend self-care first line, however there are exceptions when prescribing may be in the best interest of the patient, see [local guidelines](#) for more information. For this reason the formulary does include preparations suitable for self-care, however self-care or OTC (over the counter) will be flagged as first line within the chapter / section where relevant. (Note as chapters are being reviewed we will make sure this is captured in a standard format)

The Formulary is subject to continuous review in order to respond to changes in clinical practice including national guidance, the marketing and licensing of new products and changes to licensed indications of drugs.

Further Information

Information and advice on the use of medicines is readily available from the medicines optimisation team 0114 305 1667.

Comments

The success of the Sheffield Formulary depends on the active support of all prescribers. The Area Prescribing Group welcomes feedback and constructive comment from users. If you have any suggestions or comments please direct these in the first instance to the [APG mailbox](#) or:

Gary Barnfield
Deputy Director of Medicines Optimisation and Allied Healthcare Professionals
NHS Sheffield Clinical Commissioning Group
722 Prince of Wales Road
Darnall
Sheffield S9 4EU
garybarnfield@nhs.net Tel. 0114 3051135
March 2019

Using the Formulary – Anatomy of Entries

If the chapter includes preparations where self-care is first line, this will be flagged by either; a message like this, a message within the chapter entry or by 'OTC' annotated within the product entry

Sheffield self-care guidance encourages the use of Over the Counter (OTC) products for minor illnesses, such as xxxx. Please see [Sheffield self-care guidance](#) for full details and <https://www.nhs.uk/> for self-care information

Formulary Chapter -
Corresponds to BNF
Chapter

Chapter Topic/
Therapeutic Area

1: Gastrointestinal System

Over the counter -
Indicates available
without prescription.
[Self-care](#) first line
Also see [Glossary](#)

BNF Section
No (note this is
based on

1.1.1.

Simple antacids

Co-magaldrox (Maalox®) suspension

- OTC

Drug class
or Indication

1.1.3

Compound alginate antacids

Peptac® sugar-free suspension, contains isopropyl alcohol (available OTC)
Infant Gaviscon sachets

Gaviscon Advance® oral suspension is not recommended. Peptac is equivalent to Gaviscon which is no longer prescribable. Note – Preparations, such as Gaviscon chewable tablets, are available over the counter.

Additional Prescribing
Information

Recommended 'First
Line' therapy in bold